RE: makes me wonder7 Jul 2022 23:14
I don't think that BIO had a heads up with regards to the RNS, simply a coincidence.
Also, was the RNS that much of a surprise? NCYT gave us all a heads up at the end of April, within the Annual Results. We are all aware that testing continued to decline around the globe, plus no company announcement with regards to new contracts.
Still think that NCYT are playing their cards close to the chest, with plenty going on behind the scenes which they are unable to report upon. Today's RNS was a Trading and Strategy update, not an R&D update.
I think that a transitionary period was to be expected, it takes time to develop and launch new products.
Why did the CEO and CFO both invest at the end of Q1, both already aware of the decline in revenues and the expected escalation of the DHSC dispute?